Liminatus Pharma (LIMN) Competitors $4.83 +0.13 (+2.77%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsTrendsBuy This Stock LIMN vs. ATYR, SVRA, ARVN, CGEM, GOSS, SNDL, CYRX, PRTC, KOD, and TECXShould you be buying Liminatus Pharma stock or one of its competitors? The main competitors of Liminatus Pharma include aTyr Pharma (ATYR), Savara (SVRA), Arvinas (ARVN), Cullinan Therapeutics (CGEM), Gossamer Bio (GOSS), SNDL (SNDL), CryoPort (CYRX), PureTech Health (PRTC), Kodiak Sciences (KOD), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry. Liminatus Pharma vs. Its Competitors aTyr Pharma Savara Arvinas Cullinan Therapeutics Gossamer Bio SNDL CryoPort PureTech Health Kodiak Sciences Tectonic Therapeutic aTyr Pharma (NASDAQ:ATYR) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership. Which has higher valuation & earnings, ATYR or LIMN? Liminatus Pharma has lower revenue, but higher earnings than aTyr Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioaTyr Pharma$230K2,027.65-$64.02M-$0.81-6.47Liminatus PharmaN/AN/AN/AN/AN/A Is ATYR or LIMN more profitable? Liminatus Pharma's return on equity of 0.00% beat aTyr Pharma's return on equity.Company Net Margins Return on Equity Return on Assets aTyr PharmaN/A -87.09% -64.77% Liminatus Pharma N/A N/A N/A Does the media refer more to ATYR or LIMN? In the previous week, Liminatus Pharma had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 5 mentions for Liminatus Pharma and 4 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.88 beat Liminatus Pharma's score of 0.05 indicating that aTyr Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liminatus Pharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ATYR or LIMN? aTyr Pharma presently has a consensus price target of $20.20, indicating a potential upside of 285.50%. Given aTyr Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe aTyr Pharma is more favorable than Liminatus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Liminatus Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders have more ownership in ATYR or LIMN? 61.7% of aTyr Pharma shares are owned by institutional investors. 3.7% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryaTyr Pharma beats Liminatus Pharma on 8 of the 11 factors compared between the two stocks. Get Liminatus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIMN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIMN vs. The Competition Export to ExcelMetricLiminatus PharmaBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$122.27M$216.36M$2.53B$9.57BDividend YieldN/AN/A2.57%4.18%P/E RatioN/AN/A22.2225.14Price / SalesN/AN/A90.38104.25Price / CashN/AN/A26.8658.58Price / BookN/AN/A37.255.59Net IncomeN/AN/A$28.61M$265.48M7 Day Performance-22.97%-7.66%0.51%-0.41%1 Month Performance-30.30%-25.08%1.24%1.39%1 Year PerformanceN/A152.44%31.99%24.69% Liminatus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIMNLiminatus PharmaN/A$4.83+2.8%N/AN/A$122.27MN/A0.00N/AATYRaTyr Pharma2.601 of 5 stars$5.34+2.3%$20.20+278.3%+185.6%$475.26M$230K-6.5953Earnings ReportUpcoming EarningsSVRASavara2.0016 of 5 stars$2.74+1.5%$5.60+104.4%-34.4%$473.58MN/A-5.7120Upcoming EarningsARVNArvinas3.5178 of 5 stars$6.43-15.5%$20.29+215.5%-74.5%$469.33M$263.40M-9.74420News CoverageEarnings ReportAnalyst ForecastGap UpHigh Trading VolumeCGEMCullinan Therapeutics1.8525 of 5 stars$7.88-2.5%$30.00+280.7%-54.2%$465.00MN/A-2.7130News CoverageEarnings ReportGOSSGossamer Bio3.9236 of 5 stars$1.98-8.3%$8.50+329.3%+137.7%$450.05M$114.70M-8.61180News CoveragePositive NewsEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionHigh Trading VolumeSNDLSNDL2.8001 of 5 stars$1.69+1.8%$4.00+136.7%-19.9%$444.10M$671.81M-6.262,516Earnings ReportAnalyst RevisionCYRXCryoPort3.6557 of 5 stars$8.75+29.8%$11.60+32.6%+12.3%$438.70M$232.13M-3.741,186Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionGap UpHigh Trading VolumePRTCPureTech Health1.8188 of 5 stars$18.20-0.4%$45.00+147.3%-13.9%$437.16M$4.83M0.00100KODKodiak Sciences2.4226 of 5 stars$8.21+1.5%$9.00+9.6%+228.4%$433.16MN/A-2.2690Upcoming EarningsTECXTectonic Therapeutic2.5446 of 5 stars$23.16+2.8%$80.33+246.9%+37.0%$432.40MN/A-3.17120News CoverageEarnings ReportUpcoming Earnings Related Companies and Tools Related Companies aTyr Pharma Competitors Savara Competitors Arvinas Competitors Cullinan Therapeutics Competitors Gossamer Bio Competitors SNDL Competitors CryoPort Competitors PureTech Health Competitors Kodiak Sciences Competitors Tectonic Therapeutic Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIMN) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liminatus Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liminatus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIMN Stock Alerts